论文部分内容阅读
目的 验证血脂康对老年原发性高脂血症的调脂作用及安全性。方法 58例老年原发性高脂血症服用血脂康(600mg二次/日)治疗,服药前及服药后4、8周测定血脂、肝肾功能等,其中20例8周后减半量(600mg一次/日)维持8周。再测血脂等指标。结果 (1)血脂康治疗4周时,TC和TG分别下降20.67％和21.66％,HDL-C上升17.71％,差异显著,至8周时,TC和TG下降达25.95％和34.4％,HDL-C上升21.88％,疗效更显著。(2)减半量维持治疗,血脂维持稳定,未见反弹。(3)无明显肝、肾功能损害等毒副反应。结论:血脂康可显著降低老年原发性高脂血症的TC和TG,安全可靠,疗效显著。后减量维持疗效稳定。
Objective To verify the effect of Xuezhikang on the lipid regulation and safety of elderly patients with primary hyperlipidemia. Methods 58 cases of elderly patients with primary hyperlipidemia Xuezhikang (600mg second / day) treatment, medication and 4,8 weeks after taking the determination of blood lipids, liver and kidney function, of which 20 cases after 8 weeks by half the amount of 600mg once / day) for 8 weeks. Retest blood lipids and other indicators. Results (1) TC and TG decreased by 20.67% and 21.66% and HDL-C increased by 17.71% at 4 weeks after treatment with Xuezhikang, respectively. By 8 weeks, TC and TG decreased by 25.95% and 34.4% C increased 21.88%, the effect is more significant. (2) reduce the amount of maintenance treatment, blood lipids remain stable, no rebound. (3) no obvious liver, kidney damage and other toxic side effects. Conclusion: Xuezhikang can significantly reduce elderly patients with primary hyperlipidemia TC and TG, safe and reliable, significant effect. Subtraction to maintain a stable effect.